6A
6A3A.F Autolus Therapeutics plc
- Market cap
- EUR 298M
- P/E
- -
- P/B
- 4.39x
- ROE
- -295.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6A3A.F undervalued?
Graham numberThe Graham number of Autolus Therapeutics plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Autolus Therapeutics plc fundamental analysis
No fundamental analysis for Autolus Therapeutics plc yet.
Autolus Therapeutics plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multi…
Full company profileAutolus Therapeutics plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Autolus Therapeutics plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.69M | 1.41M | 2.91M | 242K | 2.33M | 6.19M | 1.70M | 10.1M | 75.4M | 144M |
| Gross Profit | - | - | - | - | - | - | 1.70M | -1.27M | -21.0M | 53.7M |
| Operating Income | -23.4M | -57.5M | -142M | -168M | -164M | -168M | -176M | -241M | -271M | -207M |
| EBITDA | -22.4M | -55.8M | -137M | -162M | -156M | -157M | -157M | -202M | -239M | -191M |
| Net Income | -19.7M | -44.8M | -124M | -142M | -142M | -149M | -208M | -221M | -288M | -221M |
| EPS | -0.52 | -1.11 | -2.75 | -2.71 | -1.56 | -0.86 | -1.20 | -0.83 | -1.08 | -0.83 |
| Balance Sheet | ||||||||||
| Total Assets | 149M | 273M | 304M | 294M | 406M | 490M | 375M | 783M | 589M | 493M |
| Total Liabilities | 6.06M | 17.7M | 48.7M | 84.2M | 92.2M | 192M | 264M | 355M | 411M | 418M |
| Shareholders' Equity | 143M | 255M | 255M | 210M | 313M | 299M | 111M | 427M | 178M | 74.8M |
| Cash & Short-term Investments | 137M | 247M | 211M | 153M | 310M | 382M | 240M | 227M | 104M | 171M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -16.4M | -42.5M | -101M | -118M | -118M | -112M | -146M | -206M | -284M | -181M |
| Capital Expenditure | 2.88M | 12.8M | 18.3M | 14.7M | 8.86M | 10.8M | 11.0M | 34.8M | 27.1M | 7.20M |
| Free Cash Flow | -19.2M | -41.1M | -120M | -132M | -127M | -123M | -157M | -241M | -311M | -188M |
| Ratios | ||||||||||
| ROE | -13.8% | -17.5% | -48.6% | -67.7% | -45.4% | -49.8% | -186.9% | -51.6% | -161.4% | -295.9% |
| ROA | -13.3% | -16.4% | -40.8% | -48.3% | -35.0% | -30.4% | -55.5% | -28.2% | -48.8% | -44.9% |
| Net Profit Margin | -1,165.2% | -3,180.6% | -4,258.9% | -58,716.5% | -6,098.5% | -2,403.0% | -12,272.3% | -2,180.5% | -381.4% | -154.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Autolus Therapeutics plc dividends
Autolus Therapeutics plc has not paid dividends in the last 9 fiscal years.
Who owns Autolus Therapeutics plc
- Insiders 18.56%
- Institutions 63.26%
- Public & others 18.18%
- Shares outstanding 266M
- Free float 103M
Autolus Therapeutics plc company profile
- Company name
- Autolus Therapeutics plc
- Ticker
- 6A3A.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 752
- Fiscal year end
- December
- Address
- The Mediaworks, London, United Kingdom, W12 7FP
- Phone
- 44 20 3829 6230
- Website
- autolus.com
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics plc management
10- Dr. Christian Martin Itin Ph.D.CEO & Director · born 1964
- Dr. Martin Pule M.D., MBBSFounder, Senior VP & Chief Scientific Officer · born 1972
- Mr. Robert F. DolskiSenior VP & CFO · born 1971
- Mr. Christopher VannSenior VP & COO · born 1965
- Mr. Patrick McIlvennySenior VP of Finance, Chief Accounting Officer & Principal Accounting Officer · born 1980
- Ms. Miranda NevilleSenior VP & Chief Technology Officer · born 1975
- Mr. Alex DriggsSenior VP of Legal Affairs & General Counsel and Secretary · born 1976
- Mr. Alexander SwanSenior VP & Chief Human Resources Officer · born 1965
- Dr. Christopher Williams Ph.D.Senior VP & Chief Business Development Officer · born 1980
- Dr. Matthias Will M.D.Senior VP & Chief Development Officer · born 1973